Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
$9.96
-3.8%
$10.20
$9.20
$14.63
$1.17B1.132.04 million shs1.29 million shs
Innoviva, Inc. stock logo
INVA
Innoviva
$17.35
-0.6%
$19.38
$16.67
$22.00
$1.09B0.4808,684 shs534,757 shs
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.51
-3.2%
$1.41
$1.11
$2.04
$1.20B1.53.54 million shs2.05 million shs
Progenics Pharmaceuticals, Inc. stock logo
PGNX
Progenics Pharmaceuticals
$4.10
$4.10
$1.89
$6.37
$355.05M1.891.16 million shs34.93 million shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
+1.67%+2.48%+4.33%-2.17%-2.27%
Innoviva, Inc. stock logo
INVA
Innoviva
+0.46%-1.19%-13.53%-7.03%-11.20%
OPKO Health, Inc. stock logo
OPK
OPKO Health
+0.65%+1.30%+10.64%+15.56%+4.00%
Progenics Pharmaceuticals, Inc. stock logo
PGNX
Progenics Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
$9.96
-3.8%
$10.20
$9.20
$14.63
$1.17B1.132.04 million shs1.29 million shs
Innoviva, Inc. stock logo
INVA
Innoviva
$17.35
-0.6%
$19.38
$16.67
$22.00
$1.09B0.4808,684 shs534,757 shs
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.51
-3.2%
$1.41
$1.11
$2.04
$1.20B1.53.54 million shs2.05 million shs
Progenics Pharmaceuticals, Inc. stock logo
PGNX
Progenics Pharmaceuticals
$4.10
$4.10
$1.89
$6.37
$355.05M1.891.16 million shs34.93 million shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
+1.67%+2.48%+4.33%-2.17%-2.27%
Innoviva, Inc. stock logo
INVA
Innoviva
+0.46%-1.19%-13.53%-7.03%-11.20%
OPKO Health, Inc. stock logo
OPK
OPKO Health
+0.65%+1.30%+10.64%+15.56%+4.00%
Progenics Pharmaceuticals, Inc. stock logo
PGNX
Progenics Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
2.20
Hold$24.33144.31% Upside
Innoviva, Inc. stock logo
INVA
Innoviva
2.71
Moderate Buy$37.60116.71% Upside
OPKO Health, Inc. stock logo
OPK
OPKO Health
2.50
Moderate Buy$2.6373.84% Upside
Progenics Pharmaceuticals, Inc. stock logo
PGNX
Progenics Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest PGNX, OPK, DVAX, and INVA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/8/2025
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D)
10/8/2025
Innoviva, Inc. stock logo
INVA
Innoviva
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHoldStrong-Buy
10/8/2025
Innoviva, Inc. stock logo
INVA
Innoviva
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C)
10/8/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
9/30/2025
Innoviva, Inc. stock logo
INVA
Innoviva
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageSell$17.00
9/30/2025
Innoviva, Inc. stock logo
INVA
Innoviva
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageSell$17.00
9/27/2025
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D)
9/27/2025
Innoviva, Inc. stock logo
INVA
Innoviva
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C)
9/27/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
8/22/2025
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
JMP Securities
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform$32.00
8/14/2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong SellHold
(Data available from 10/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
$277.25M4.21$0.15 per share64.29$4.54 per share2.19
Innoviva, Inc. stock logo
INVA
Innoviva
$370.23M2.95$3.42 per share5.07$11.03 per share1.57
OPKO Health, Inc. stock logo
OPK
OPKO Health
$713.10M1.68$0.07 per share22.53$2.00 per share0.76
Progenics Pharmaceuticals, Inc. stock logo
PGNX
Progenics Pharmaceuticals
$34.99M10.15N/AN/A$0.54 per share7.59
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
$27.31M-$0.46N/A20.33N/A-16.67%5.10%3.00%11/6/2025 (Estimated)
Innoviva, Inc. stock logo
INVA
Innoviva
$23.39M$0.3155.9711.19N/A10.44%18.67%9.92%11/5/2025 (Estimated)
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$53.22M-$0.25N/AN/AN/A-26.68%-13.17%-8.28%11/6/2025 (Estimated)
Progenics Pharmaceuticals, Inc. stock logo
PGNX
Progenics Pharmaceuticals
-$68.55M-$0.80N/AN/AN/A-180.28%-129.46%-53.23%N/A

Latest PGNX, OPK, DVAX, and INVA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/6/2025Q3 2025
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
$0.14N/AN/AN/A$94.00 millionN/A
11/6/2025Q3 2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.03N/AN/AN/A$165.74 millionN/A
11/5/2025Q3 2025
Innoviva, Inc. stock logo
INVA
Innoviva
$0.46N/AN/AN/A$91.31 millionN/A
8/7/2025Q2 2025
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
$0.12$0.14+$0.02$0.14$87.55 million$95.44 million
8/6/2025Q2 2025
Innoviva, Inc. stock logo
INVA
Innoviva
$0.57$0.77+$0.20$0.77$87.10 million$100.28 million
7/31/2025Q2 2025
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.12-$0.19-$0.07-$0.19$165.74 million$156.80 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
N/AN/AN/AN/AN/A
Innoviva, Inc. stock logo
INVA
Innoviva
N/AN/AN/AN/AN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
N/AN/AN/AN/AN/A
Progenics Pharmaceuticals, Inc. stock logo
PGNX
Progenics Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
0.45
6.65
6.01
Innoviva, Inc. stock logo
INVA
Innoviva
0.36
2.64
2.44
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.25
3.41
3.02
Progenics Pharmaceuticals, Inc. stock logo
PGNX
Progenics Pharmaceuticals
0.99
2.12
2.12

Institutional Ownership

CompanyInstitutional Ownership
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
96.96%
Innoviva, Inc. stock logo
INVA
Innoviva
99.12%
OPKO Health, Inc. stock logo
OPK
OPKO Health
64.63%
Progenics Pharmaceuticals, Inc. stock logo
PGNX
Progenics Pharmaceuticals
70.96%

Insider Ownership

CompanyInsider Ownership
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
2.98%
Innoviva, Inc. stock logo
INVA
Innoviva
2.25%
OPKO Health, Inc. stock logo
OPK
OPKO Health
49.69%
Progenics Pharmaceuticals, Inc. stock logo
PGNX
Progenics Pharmaceuticals
4.26%
CompanyEmployeesShares OutstandingFree FloatOptionable
Dynavax Technologies Corporation stock logo
DVAX
Dynavax Technologies
350117.27 million113.77 millionOptionable
Innoviva, Inc. stock logo
INVA
Innoviva
10063.02 million61.60 millionOptionable
OPKO Health, Inc. stock logo
OPK
OPKO Health
2,997793.78 million399.35 millionOptionable
Progenics Pharmaceuticals, Inc. stock logo
PGNX
Progenics Pharmaceuticals
7986.60 millionN/AOptionable

New MarketBeat Followers Over Time

Media Sentiment Over Time

Dynavax Technologies stock logo

Dynavax Technologies NASDAQ:DVAX

$9.96 -0.39 (-3.77%)
Closing price 04:00 PM Eastern
Extended Trading
$9.96 +0.00 (+0.05%)
As of 04:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

Innoviva stock logo

Innoviva NASDAQ:INVA

$17.35 -0.10 (-0.57%)
Closing price 04:00 PM Eastern
Extended Trading
$17.68 +0.33 (+1.93%)
As of 05:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

OPKO Health stock logo

OPKO Health NASDAQ:OPK

$1.51 -0.05 (-3.21%)
Closing price 04:00 PM Eastern
Extended Trading
$1.50 -0.01 (-0.66%)
As of 05:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

Progenics Pharmaceuticals stock logo

Progenics Pharmaceuticals NASDAQ:PGNX

Progenics Pharmaceuticals, Inc., an oncology company, develops, manufactures, and commercializes pharmaceutical products and other technologies to target, diagnose, and treat cancer cancer in the United States and internationally. The company's product candidates include Azedra, a radiotherapeutic product candidate for the treatment of iobenguane scan positive, unresectable, and locally advanced or metastatic pheochromocytoma or paraganglioma for adult and pediatric patients; PyL, a clinical-stage fluorinated prostate specific membrane antigen (PSMA)-targeted PET/CT imaging agent for prostate cancer; and 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer. Its product candidates also comprise PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in Phase I clinical trial for treatment of metastatic prostate cancer; and Leronlimab, a humanized monoclonal antibody, which is in Phase III development for the treatment of HIV infection. The company also offers Relistor-subcutaneous injection for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain or advanced-illness adult patients; Relistor tablets for the treatment of OIC in adults with chronic non-cancer pain; PSMA AI, an imaging analysis technology that uses artificial intelligence and machine learning to quantify and automate the reading of PSMA targeted imaging; and automated bone scan index, a software that quantifies the hotspots on bone scans and calculates the bone scan index value. It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in New York City, New York.